What Happens If a Cancer Patient Gets a Cold?

A common cold that would be a minor nuisance for a healthy person can become a serious medical event for someone being treated for cancer. Cancer treatments like chemotherapy suppress the immune system, leaving patients poorly equipped to fight off even ordinary respiratory viruses. In roughly a third of cases, what starts as a cold in a cancer patient can progress to pneumonia, and the stakes from there climb steeply. The reality is more layered than simple immune weakness, though, involving prolonged infections, diagnostic confusion, and treatment disruptions that ripple outward in ways most people do not anticipate.

Why Cancer Patients Are More Vulnerable

The core issue is that most cancer treatments damage the immune system as a side effect of attacking the cancer itself. Chemotherapy drugs work by targeting fast-dividing cells, which includes both tumor cells and the white blood cells your body relies on to fight infections. This is especially true of the neutrophils, a type of white blood cell that serves as the immune system’s first responder against bacteria and viruses. When neutrophil counts drop low enough, a condition called neutropenia, even a mild respiratory virus can gain a foothold that the body cannot clear on its own.¹

The type of cancer matters, too. Patients with blood cancers like leukemia or lymphoma tend to be at higher risk than those with solid tumors such as breast or colon cancer, because blood cancers directly impair the immune cells themselves. The cancer is not just competing with the immune system for resources; it is actively dismantling the machinery the body needs to recognize and destroy pathogens.

When a Cold Turns Into Pneumonia

For healthy adults, a cold stays in the upper airways: runny nose, sore throat, maybe some congestion. The immune system contains the virus before it migrates deeper. In cancer patients, that containment often fails. According to guidelines from the German Society for Haematology, community-acquired respiratory virus infections in cancer patients progress to pneumonia in about 30% of cases, with mortality around 25% among those who develop pneumonia.² Those numbers are striking when you consider that pneumonia from a cold virus is rare in the general population.

The risk is not limited to viral pneumonia alone. A weakened respiratory tract is an invitation for bacterial infections to pile on. Patients with cancer already face structural changes to lung tissue from tumors, radiation, or surgery, and chemotherapy-induced drops in white blood cells remove yet another line of defense. Bacterial pneumonia in this population carries high morbidity, driven by factors ranging from impaired swallowing function to complex immune defects tied to treatment.³ In practice, many severe respiratory infections in cancer patients involve both a virus and bacteria working in tandem.

Which Viruses Are Most Dangerous

Not all cold viruses carry the same risk. Rhinovirus, the most common cause of the everyday cold, is usually less threatening than several other respiratory viruses that circulate in the same seasons. Respiratory syncytial virus, or RSV, stands out as particularly dangerous for cancer patients. In children with blood cancers, RSV was associated with a fourfold increase in the odds of severe outcomes compared to other respiratory viruses.⁴ A large retrospective study of immunocompromised children found RSV to be the most commonly identified respiratory virus, and 10% of the patients in that cohort died, with the majority of deaths at least partly attributed to a respiratory viral infection.⁵

Influenza and parainfluenza also pose elevated risks. Treatment options exist for some of these viruses but not all. Influenza can be treated with antiviral drugs like oseltamivir, and RSV infections are sometimes managed with ribavirin and intravenous immunoglobulins. For parainfluenza and human metapneumovirus, the evidence supporting antiviral treatment remains inconclusive.² This uneven treatment landscape means that which virus a cancer patient catches can matter as much as how suppressed their immune system is.

Neutropenic Fever Is a Medical Emergency

One of the most critical things for cancer patients and their families to understand is that a fever during treatment is not something to wait out. Neutropenic fever, defined as a single temperature at or above 38.3°C (about 101°F) or a sustained temperature at or above 38.0°C for an hour in someone with very low neutrophil counts, is treated as a medical emergency.⁶ Clinicians aim to start broad-spectrum antibiotics within one hour of presentation, because the infection source is often unclear at first and can escalate rapidly.

This matters in the context of a cold because the early symptoms overlap: low-grade fever, fatigue, general malaise. A cancer patient who assumes their fever is from a harmless virus and waits a day or two to see if it passes may be losing critical time. Oncology teams drill this into patients before each chemotherapy cycle, but the advice bears repeating. If you are on active cancer treatment and you develop a fever, call your care team immediately, regardless of whether it feels like “just a cold.”

Why Colds Last Longer in Cancer Patients

Beyond being more dangerous, respiratory infections also tend to linger in people whose immune systems are compromised by cancer or its treatment. A study of cancer patients infected with SARS-CoV-2 found they were nearly twice as likely to shed the virus for a week or longer compared to non-cancer patients.⁷ Among cancer patients specifically, those with blood cancers shed virus for significantly longer than those with solid tumors.⁸

Prolonged shedding matters for two reasons. First, it means the patient remains sick and potentially contagious for longer, which creates isolation challenges and makes it harder to resume cancer treatment on schedule. Second, the longer a virus replicates inside a host, the more chances it has to mutate. This is not just a theoretical concern: researchers have documented the emergence of drug-resistant viral mutations in immunocompromised patients. In one case, an immunocompromised patient treated with oseltamivir for pandemic influenza developed a resistant viral strain that originated in the nasopharynx and then spread to the lungs.⁹ Similar patterns were observed during the COVID-19 pandemic, where new mutations appeared in cancer patients undergoing treatment, including mutations associated with antiviral drug resistance.¹⁰

This viral evolution inside immunocompromised patients has implications beyond the individual. It is one of the pathways through which new, potentially more resistant variants enter the broader population. Early in the pandemic, several scientists pointed to prolonged infections in immunocompromised patients as a plausible origin for heavily mutated variants.

Vaccination Works Differently During Treatment

The obvious question is whether cancer patients can simply get vaccinated against flu, RSV, and other respiratory viruses to avoid these complications. They can and generally should, but the protection they receive is often substantially weaker than what a healthy person gets from the same vaccine. A study comparing flu vaccine responses found that after two vaccine doses, healthy individuals achieved seroprotection rates around 96%, patients with solid tumors reached about 90%, but patients with blood cancers during therapy managed only 67%.¹¹ The gap was even more dramatic by another measure: only 13% of blood cancer patients showed evidence of a meaningful antibody response, compared to 74% of healthy individuals.

This does not mean vaccination is pointless for cancer patients. Even a partial immune response can reduce the severity of an infection, turning what might have been pneumonia into a bad week of cold symptoms. But it does mean that cancer patients cannot rely on vaccination alone and should combine it with other protective strategies. Oncologists sometimes time vaccination around chemotherapy cycles to maximize the immune response, since the days immediately after a chemo infusion are when the immune system is most battered.¹²

Equally important is what the medical community calls “cocooning”: making sure that the people around the cancer patient are vaccinated. Household members, close friends, and caregivers who stay current on their flu and COVID vaccines create a buffer zone that reduces the patient’s exposure in the first place.

Respiratory Infections After Newer Cancer Therapies

The conversation about cancer and colds is evolving as newer treatments become more common. CAR T-cell therapy, which reprograms a patient’s own immune cells to attack cancer, has been transformative for certain blood cancers. But the treatment comes with prolonged immune suppression that can last months or even years. In one study, roughly one in five patients developed a respiratory viral infection within 18 months of CAR T-cell therapy, with the majority of those infections occurring more than six months after treatment.¹³ Most were mild upper respiratory infections, but all of the moderate-to-severe cases involved the lower respiratory tract.

The mechanism behind this vulnerability involves multiple overlapping deficits. CAR T-cell patients typically receive lymphocyte-depleting chemotherapy before the treatment, often have underlying blood cancers that already weaken immunity, and frequently develop prolonged, severe hypogammaglobulinemia, meaning their bodies cannot produce adequate levels of the antibodies needed to neutralize viruses.¹⁴ That low antibody state was the strongest predictor of late respiratory infections in one analysis, with a sixfold increase in risk.¹⁵ For these patients, the window of heightened vulnerability to something as simple as a cold extends far beyond the treatment period itself.

When Cold Symptoms Are Not Actually a Cold

A separate but underappreciated concern is that cold-like symptoms in a cancer patient may not be caused by a virus at all. In one case report, a middle-aged man with persistent cold symptoms that would not resolve turned out to have acute myeloid leukemia, a blood cancer that was mimicking an ordinary upper respiratory infection.¹⁶ While this is an unusual presentation, it illustrates a broader point: in someone with cancer, the diagnostic picture is muddied. Symptoms that look like a cold could stem from a virus, a bacterial infection, a drug reaction, or progression of the cancer itself.

This diagnostic ambiguity influences how hospitals manage cancer patients who arrive with respiratory symptoms and fever. A study of pediatric cancer patients admitted with fever and neutropenia found that sending a respiratory viral panel did not significantly change length of stay or clinical outcomes, in part because the management approach (start antibiotics quickly, monitor closely) was the same regardless of whether a virus was identified.¹⁷ The average hospital stay for these children was about six and a half days, a reminder that what might be a two-day inconvenience for a healthy child can mean nearly a week of inpatient care for one with cancer.

Treatment Disruptions and Their Ripple Effects

Perhaps the most overlooked consequence of a cancer patient catching a cold is what happens to their cancer treatment. Chemotherapy and other therapies often run on tightly scheduled cycles, and an active infection can force oncologists to delay or reduce doses. A cold that keeps a patient’s white blood cell counts suppressed for an extra week can push back the next round of treatment, and those delays can have real consequences for outcomes depending on the cancer type and stage.

The psychological toll of treatment disruption adds another layer. During the COVID-19 pandemic, researchers found that cancer patients whose treatment was delayed experienced significantly higher levels of depression and anxiety, with a strong positive correlation between the length of treatment disruption and the severity of psychological distress.¹⁸ A separate study confirmed that treatment delays were also linked to higher rates of post-traumatic stress symptoms, and that patients who lacked clear communication with their oncology teams during the disruption fared worst.¹⁹

Even outside a pandemic context, the anxiety cycle is familiar to many cancer patients: fear of catching something leads to social isolation, which leads to loneliness, which worsens mental health, which can affect treatment adherence and recovery. A cold is never just a cold when it threatens the timeline of your cancer treatment, and the stress of that reality compounds the physical illness.

Practical Steps That Actually Reduce Risk

Given all of this, what should cancer patients and their families actually do? The basics are simple but matter enormously. Frequent handwashing remains one of the most effective ways to prevent respiratory virus transmission. Avoiding crowded indoor spaces during peak cold and flu season, wearing a well-fitting mask when exposure is unavoidable, and asking visitors to stay away when they feel unwell are all strategies that oncology teams recommend routinely.

Beyond personal precautions, the people surrounding a cancer patient play a critical role. Household vaccination, as mentioned earlier, creates a protective barrier. Children in the household are especially important to vaccinate, since they tend to pick up respiratory viruses at school and bring them home. If a family member does develop a cold, isolating within the home as much as possible and using separate bathrooms when available can reduce transmission.

For the patient, keeping a thermometer on hand and knowing exactly when to call the oncology team is essential. The threshold for concern is lower than for a healthy person. Any fever, any worsening of respiratory symptoms, any new shortness of breath warrants a call. Most oncology practices have 24-hour on-call lines specifically because infections in their patients can deteriorate quickly. Waiting until morning or assuming it will pass on its own is the single most common and most dangerous mistake cancer patients make with infections.